POST Online Media Lite Edition



 

West Virginia seeks Mylan records on EpiPen price

Staff Writer |
West Virginia sought court enforcement of a subpoena that seeks answers from Mylan about the price the pharmaceutical company imposed for its EpiPen lifesaving allergy injectors.

Article continues below






The court petition is part of an investigation that could lead to Medicaid fraud charges against Mylan.

"In 2007, Mylan acquired the exclusive rights to market the EpiPen, a single-use product that counteracts the effects of an allergic anaphylactic reaction that could result in death of the victim.

"The active pharmaceutical ingredient in the EpiPen is epinephrine, which is not covered by a patent. Some parts of the mechanism that deliver the Epi-Pen's single-use dose of epinephrine, however, are patented.

"The price for the EpiPen has increased dramatically since Mylan acquired the exclusive rights to distribute it. In 2009, the price for an EpiPen twin pack was about $100.00. Currently, the price for an EpiPen twin pack exceeds $600.00.

"Mylan's net sales of the EpiPen, worldwide, were about $1 billion in each of 2014 and 2015.

"Mylan provided initial answers to the subpoena issued on August 26, but missed a September 7 deadline to provide all the requested information, West Virginia Attorney General Patrick Morrisey said in the petition filed in the Circuit Court of Kanawha County.

"The company claimed it could not provide further information until after the Capitol Hill hearings, which "could continue for weeks," the petition said," the court petition says.


What to read next

CVS starts selling Impax's cheaper version of Epipen
Mylan to launch generic EpiPen at 50% discount
Mylan offers discounts on EpiPen after wave of criticism